Eli Lilly and Company (LLY)

118.23
NYSE
Prev Close 118.00
Day Low/High 116.75 / 118.67
52 Wk Low/High 77.09 / 132.13
Exchange NYSE
Shares Outstanding 1035.82B
Market Cap 122.23B
Div & Yield N.A. (N.A)

Takeaways & Observations

"I had nothing to offer anybody except my own confusion." -- Jack Kerouac  So, color me confused. But I will persevere and write "Takeaways!"  While a lot didn't make sense, I suspect many traders/investors were caught "offsides."  Peter Boockvar do...

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Eli Lilly: Here's One Drug Company Ready to Rally

Eli Lilly: Here's One Drug Company Ready to Rally

Traders should look to go long on a close above $84.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Cowen Health Care Conf.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Snapchat's Parent Prices IPO at Low End of Expectations

Snapchat's Parent Prices IPO at Low End of Expectations

Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

My Takeaways and Observations

I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure.   In other words, I am sticking to my script...

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Eli Lilly upgraded at Morgan Stanley

My Takeaways and Observations

Slow day, at meetings all morning.   Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing.   I reflected on my July call that we have hit a Genera...

Inside Eli Lilly's Surging Stock Price

Inside Eli Lilly's Surging Stock Price

For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

The Good, the Bad and the Ugly

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...